Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OnabotulinumtoxinA for multiple sclerosis tremor
ACTRN12617000379314Phase 3Active, not recruiting
- Sponsor
- University of Melbourne
- Start
- Aug 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple sclerosis (MS) comparing OnabotulinumtoxinA with Placebo (2 arms). Primary endpoints: Overall tremor severity response by Bain score, Writing tremor response by Bain writing score and 1 more. Started Aug 2016; status: active, not recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on ACTRN12617000379314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000379314.